Infect Chemother.
2025 Mar;57(1):168-171. 10.3947/ic.2024.0131.
Cytomegalovirus Retinitis in a Hematopoietic Stem Cell Transplant Recipient During Maribavir Pre-emptive Therapy
- Affiliations
-
- 1Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 3Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2566772
- DOI: http://doi.org/10.3947/ic.2024.0131
Abstract
- We report a case of cytomegalovirus retinitis in a hematopoietic stem cell transplant recipient during valganciclovir pre-emptive therapy followed by maribavir. Analysis of UL97 mutation revealed a C480F substitution associated with high maribavir resistance and low ganciclovir resistance.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- CMV antigenemia following pediatric hematopoietic stem cell transplantation:risk factors and outcomes
- Infection Prevention in Transplant Recipients
- Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy
- CMV Papillitis in Renal Transplant Recipient
- Characteristics of Cytomegalovirus Diseases among Hematopoietic Stem Cell Transplant Recipients : A 10-year Experience at an University Hospital in Korea
